Phase I/II study of ABTL0812 in pediatric patients with neuroblastoma

Trial Profile

Phase I/II study of ABTL0812 in pediatric patients with neuroblastoma

Planning
Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2015

At a glance

  • Drugs ABTL 0812 (Primary)
  • Indications Neuroblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Apr 2015 New trial record
    • 07 Apr 2015 The Committee for Orphan Drug Products (COMP) of the EMA has issued a positive opinion on the application for orphan drug designation of the investigational compound ABTL0812 for the treatment of neuroblastoma in a pediatric population, according to an Ability media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top